Contact:

Frank DeSanto, Communications Manager, SWOG Cancer Research Network, fdesanto@swog.org, 210.718.2941

Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research, rhohman@focr.org, 202.944.6708

Lung-MAP Master Protocol Model Broadens Trial Access for Some Underrepresented Groups

As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.

These are some of the results of an analysis of the representativeness of the more than 3,500 patients enrolled to Lung-MAP from its 2014 launch through 2020. That work is being published in the journal JCO Precision Oncology.

Riha Vaidya, PhD, of the SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center, is lead author on the analysis.

“Lung-MAP is the first protocol conducted within the NCTN as a public–private partnership,” Vaidya said, referring to the National Clinical Trials Network. “There isn’t any published data on whether this partnership approach improves access to clinical trials over conventionally conducted trials. So, our goal was to examine the sociodemographic characteristics of patients enrolled to Lung-MAP and how they compared to other SWOG trials for advanced NSCLC.”

The Lung-MAP partnership includes the National Cancer Institute (NCI) – part of the National Institutes of Health (NIH) – and its NCTN, including SWOG Cancer Research Network, and Friends of Cancer Research, the Foundation for the National Institutes of Health, Foundation Medicine, pharmaceutical companies that provide their drugs for the study, and several lung cancer advocacy organizations. The trial provides an infrastructure for conducting a portfolio of biomarker-driven clinical trials in NSCLC under a shared screening protocol.

A group of Lung-MAP researchers set out to determine whether the master protocol approach improved access to trials, particularly for groups historically underrepresented in clinical research studies.

The team examined sociodemographic characteristics for all 3,556 patients enrolled to the Lung-MAP screening protocol between the activation of the study in June 2014 and December 31, 2020. They compared Lung-MAP participant characteristics to those from a set of 2,215 patients enrolled to other, individual clinical trials in advanced NSCLC that were conducted by the SWOG Cancer Research Network.

Compared to patients enrolled to other NSCLC studies, Lung-MAP patients were more likely to be 65 years of age or older (57.2 percent versus 46.3 percent), to live in a rural area (17.3 percent versus 14.4 percent), to live in a neighborhood classified as socioeconomically deprived based on its Area Deprivation Index score (42.2 percent versus 36.7 percent), or to have Medicaid insurance or no health insurance (of patients younger than 65, 27.6 percent versus 17.8 percent).

Patients on Lung-MAP, however, were less likely than those enrolled on other trials to be female (38.6 percent versus 47.2 percent), to be Asian (2.8 percent versus 5.1 percent), or to be Hispanic (2.4 percent versus 3.8 percent). In explaining the underrepresentation of female patients, the authors note that before 2019, Lung-MAP enrollment was limited to patients with squamous cell carcinoma, a tumor histology that is significantly more common among men.

“Our finding of improved access to clinical trials for some underrepresented patient groups provides an opportunity to examine how we can apply site and patient engagement practices from Lung-MAP to other trials so we can reach more patients,” Vaidya said. “We have more work to do, particularly regarding representation of racial and ethnic minority groups. SWOG’s DEI infrastructure will be critical in identifying and resolving barriers to trial access for these patient groups.”

The work was funded by the NCI/NIH through grants CA180888, CA180819, CA180820, CA180821, CA180868, CA189858, CA189821, CA189830, CA239767, CA189971, CA180826, CA180828, CA180846, and CA180858 and in part by AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, and Pfizer through the Foundation for the National Institutes of Health, in partnership with Friends of Cancer Research.

In addition to Dr. Vaidya, co-authors on the paper include Joseph M. Unger, PhD, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Lu Qian, MS, Fred Hutchinson Cancer Center; Katherine Minichiello, MS, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Roy S. Herbst, MD, Yale Cancer Center; David R. Gandara, MD, UC Davis Comprehensive Cancer Center; Joel W. Neal, MD PhD, Stanford Cancer Institute; Ticiana A. Leal, MD, Winship Cancer Institute, Emory University; Jyoti D. Patel, MD, Northwestern University Feinberg School of Medicine; Konstantin H. Dragnev, MD, Dartmouth Cancer Center; Saiama N. Waqar, MD, Washington University School of Medicine; Martin J. Edelman, MD, Fox Chase Cancer Center, Temple University Health System; Ellen V. Sigal, PhD, Friends of Cancer Research; Stacey J. Adam, PhD, Foundation for the National Institutes of Health; Shakun Malik, MD, National Cancer Institute; Charles D. Blanke, MD, SWOG Cancer Research Network and Oregon Health and Science University; Michael L. LeBlanc, PhD, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Karen Kelly, MD, UC Davis Comprehensive Cancer Center; Jhanelle E. Gray, MD, Moffitt Cancer Center; and Mary W. Redman, PhD, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center.

Reference:
Vaidya R, Unger JM, Qian L, et al. “Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).” DOI: 10.1200/PO.23.00218 JCO Precision Oncology no. 7 (2023) e2300218. Published online September 7, 2023.

About Lung-MAP

Lung-MAP is a unique, collaborative cancer clinical trial that uses genetic screening to match patients to investigational new treatments for non-small cell lung cancers. It is built on a groundbreaking public–private partnership that includes the NCI and its National Clinical Trials Network (NCTN) including SWOG Cancer Research Network, Friends of Cancer Research, the Foundation for the National Institutes of Health (FNIH), Foundation Medicine, pharmaceutical companies that provide their drugs for studies, and several lung cancer advocacy organizations.

With the trial offered at more than 800 U.S. medical centers and community hospitals under the NCTN and the NCI Community Oncology Research Program (NCORP), Lung-MAP makes it easier for patients to receive investigational treatments to fight their non-small cell lung cancer. Lung-MAP is more flexible, efficient, and cost-effective than traditional clinical trial models, using a single “master protocol” that is amended as drugs enter and exit the trial, which preserves infrastructure and patient outreach efforts, allowing researchers to quickly answer the critical question: Does this new drug or drug combination work?

Since its launch, Lung-MAP has registered almost 5,000 patients. Trial leaders have worked with 13 pharmaceutical partners, in coordination with the FNIH, to launch 17 studies, 15 of which are completed. The trial is addressing questions about the efficacy of immunotherapies and immunotherapy combinations and the validity of new biomarkers. The trial has also produced critical insights into the conduct of large-scale precision medicine trials, including issues related to tissue sampling and banking, genetic screening, patient communication, and trial access for members of underrepresented groups.

About the Foundation for the National Institutes of Health

The Foundation for the National Institutes of Health (FNIH) connects the world’s leading public and private organizations to accelerate biomedical breakthroughs for patients, regardless of who they are, where they live, or what disease they have. Together with leading scientists and problem-solvers, and a successful track record of navigating complex problems, the FNIH accelerates new therapies, diagnostics, and potential cures; advances global health and equity in care; and celebrates and trains the next generation of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit fnih.org.

About Friends of Cancer Research

Friends of Cancer Research (Friends) drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed lifesaving treatments to patients. For more information, please visit http://www.focr.org.

About SWOG Cancer Research Network

SWOG is part of the National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Program (NCORP) and is part of the oldest and largest publicly funded cancer research network in the nation. SWOG has more than 18,000 members in 45 states and nine other countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org, and follow us on Twitter at @SWOG.